Accropeutics Bioscience, a China-based clinical-stage biotech company, announced on Wednesday that the company has received approval from the Australian Human Research Ethics Committee (HREC) to launch a clinical phase I trial of its oral small molecule TYK2/JAK1 inhibitor AC-201 in Australia.
The trial, a randomised, double-blind, placebo-controlled, single and multiple ascending dose study, is to assess the safety, tolerability, pharmacokinetics, and food impacts of AC-201 in healthy adults.
AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have indicated that the product effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1, stabilising the self-inhibitory conformation of the pseudo kinase domain on the kinase domain, thereby inhibiting the function of TYK2/JAK1 kinase. It showcased significant efficacy in multiple animal models of diseases, including psoriasis, and is aimed at the treatment of psoriasis and other inflammatory and autoimmune diseases. The company said that it is expected to provide convenience and efficacy with good safety for psoriasis patients.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP